Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of telavancin against resistant gram-positive bacteria.

Literature DB >> 18443122

In vitro activity of telavancin against resistant gram-positive bacteria.

Kevin M Krause¹, Marika Renelli, Stacey Difuntorum, Terry X Wu, Dmitri V Debabov, Bret M Benton.

Abstract

The in vitro activity of telavancin was tested against 743 predominantly antimicrobial-resistant, gram-positive isolates. Telavancin was highly active against methicillin-resistant staphylococci (MIC(90), 0.5 to 1 microg/ml), streptococci (all MICs, < or =0.12 microg/ml), and VanB-type enterococci (all MICs, < or =2 microg/ml). Time-kill studies demonstrated the potent bactericidal activity of telavancin.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2008 PMID： 18443122 PMCID： PMC2443888 DOI： 10.1128/AAC.01398-07

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

Review 1. Antimicrobial resistance: the example of Staphylococcus aureus.

Authors: Franklin D Lowy
Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808

2. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.

Authors: W T M Jansen; A Verel; J Verhoef; D Milatovic
Journal: Antimicrob Agents Chemother Date: 2007-07-02 Impact factor: 5.191

Review 3. Gram-positive resistance: challenge for the development of new antibiotics.

Authors: F Baquero
Journal: J Antimicrob Chemother Date: 1997-05 Impact factor: 5.790

Review 4. The emergence and evolution of methicillin-resistant Staphylococcus aureus.

Authors: K Hiramatsu; L Cui; M Kuroda; T Ito
Journal: Trends Microbiol Date: 2001-10 Impact factor: 17.079

5. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.

Authors: Kimberly D Leuthner; Chrissy M Cheung; Michael J Rybak
Journal: J Antimicrob Chemother Date: 2006-06-20 Impact factor: 5.790

Review 6. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

Authors: H F Chambers
Journal: Clin Microbiol Rev Date: 1997-10 Impact factor: 26.132

Review 7. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance.

Authors: M C Maranan; B Moreira; S Boyle-Vavra; R S Daum
Journal: Infect Dis Clin North Am Date: 1997-12 Impact factor: 5.982

8. In vitro activity of TD-6424 against Staphylococcus aureus.

Authors: John L Pace; Kevin Krause; Deborah Johnston; Dmitri Debabov; Terry Wu; Lesley Farrington; Cassie Lane; Deborah L Higgins; Burt Christensen; J Kevin Judice; Koné Kaniga
Journal: Antimicrob Agents Chemother Date: 2003-11 Impact factor: 5.191

9. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2004-06 Impact factor: 5.191

10. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.

Authors: Anna King; Ian Phillips; Koné Kaniga
Journal: J Antimicrob Chemother Date: 2004-03-17 Impact factor: 5.790

10 in total

36 in total

1. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

Authors: Rodrigo E Mendes; Helio S Sader; David J Farrell; Ronald N Jones
Journal: Antimicrob Agents Chemother Date: 2012-04-16 Impact factor: 5.191

Review 2. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors: Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal: Ther Adv Infect Dis Date: 2017-03-08

3. Telavancin.

Authors: G Ralph Corey; Martin E Stryjewski; Wim Weyenberg; Uma Yasothan; Peter Kirkpatrick
Journal: Nat Rev Drug Discov Date: 2009-12 Impact factor: 84.694

4. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus.

Authors: Christopher S Lunde; Charles H Rexer; Stephanie R Hartouni; Sabine Axt; Bret M Benton
Journal: Antimicrob Agents Chemother Date: 2010-02-22 Impact factor: 5.191